Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Organogenesis Holdings Inc (NASDAQ: ORGO) closed at $3.89 down -2.02% from its previous closing price of $3.97. In other words, the price has decreased by -$2.02 from its previous closing price. On the day, 0.58 million shares were traded. ORGO stock price reached its highest trading level at $4.0441 during the session, while it also had its lowest trading level at $3.84.
Ratios:
For a deeper understanding of Organogenesis Holdings Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.45 and its Current Ratio is at 3.95. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Lake Street on June 28, 2024, initiated with a Buy rating and assigned the stock a target price of $5.
On February 07, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $5.
On June 15, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $5.Morgan Stanley initiated its Equal-Weight rating on June 15, 2023, with a $5 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 14 ’25 when NUSSDORF GLENN H bought 251,001 shares for $3.09 per share. The transaction valued at 775,041 led to the insider holds 251,001 shares of the business.
NUSSDORF GLENN H bought 107,494 shares of ORGO for $320,999 on May 15 ’25. The Director now owns 358,495 shares after completing the transaction at $2.99 per share. On Jun 10 ’25, another insider, NUSSDORF GLENN H, who serves as the Director of the company, sold 18,620 shares for $3.56 each. As a result, the insider received 66,256 and left with 335,719 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ORGO now has a Market Capitalization of 493476512 and an Enterprise Value of 589193472. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.15 while its Price-to-Book (P/B) ratio in mrq is 2.12. Its current Enterprise Value per Revenue stands at 1.372 whereas that against EBITDA is 186.1.
Stock Price History:
The Beta on a monthly basis for ORGO is 1.50, which has changed by 0.21036589 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, ORGO has reached a high of $6.71, while it has fallen to a 52-week low of $2.61. The 50-Day Moving Average of the stock is -11.94%, while the 200-Day Moving Average is calculated to be -7.41%.
Shares Statistics:
For the past three months, ORGO has traded an average of 779.45K shares per day and 1010010 over the past ten days. A total of 126.85M shares are outstanding, with a floating share count of 59.76M. Insiders hold about 52.89% of the company’s shares, while institutions hold 56.31% stake in the company. Shares short for ORGO as of 1760486400 were 11110375 with a Short Ratio of 14.25, compared to 1757894400 on 10862542. Therefore, it implies a Short% of Shares Outstanding of 11110375 and a Short% of Float of 25.47.
Earnings Estimates
Its stock is currently analyzed by 1.0 different market analysts. The consensus estimate for the next quarter is $0.18, with high estimates of $0.18 and low estimates of $0.18.
Analysts are recommending an EPS of between $0.08 and $0.08 for the fiscal current year, implying an average EPS of $0.08. EPS for the following year is $0.17, with 1.0 analysts recommending between $0.17 and $0.17.
Revenue Estimates
A total of 1 analysts believe the company’s revenue will be $135M this quarter.It ranges from a high estimate of $135M to a low estimate of $135M. As of. The current estimate, Organogenesis Holdings Inc’s year-ago sales were $115.18MFor the next quarter, 1 analysts are estimating revenue of $166.55M. There is a high estimate of $172M for the next quarter, whereas the lowest estimate is $161.1M.
A total of 2 analysts have provided revenue estimates for ORGO’s current fiscal year. The highest revenue estimate was $510.2M, while the lowest revenue estimate was $483.9M, resulting in an average revenue estimate of $497.05M. In the same quarter a year ago, actual revenue was $482.04MBased on 2 analysts’ estimates, the company’s revenue will be $620.95M in the next fiscal year. The high estimate is $690.8M and the low estimate is $551.1M.
